StockData
IN8bio, Inc. logo

IN8bio, Inc. (INAB) stock

INABNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.78−0.04 (-4.88%)

Close on Nov 18, 2026Market cap $7.69MP/E –Yield –

IN8bio operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

IN8bio's operating income for the twelve months ending Jun 30, 2026 was -$18.67M. For fiscal 2025 it was -$19.44M. The highest annual figure on record is -$8.56M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$19.44M–
FY2024Dec 31, 2024-$30.44M–
FY2023Dec 31, 2023-$30.01M–
FY2022Dec 31, 2022-$28.52M–
FY2021Dec 31, 2021-$14.65M–
FY2020Dec 31, 2020-$8.56M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.78M–
Q1 FY2026Mar 31, 2026-$5.09M–
Q4 FY2025Dec 31, 2025-$4.94M–
Q3 FY2025Sep 30, 2025-$3.85M–
Q2 FY2025Jun 30, 2025-$5.09M–
Q1 FY2025Mar 31, 2025-$5.55M–
Q4 FY2024Dec 31, 2024-$6.16M–
Q3 FY2024Sep 30, 2024-$7.09M–
Q2 FY2024Jun 30, 2024-$8.63M–
Q1 FY2024Mar 31, 2024-$8.56M–
Q4 FY2023Dec 31, 2023-$7.60M–
Q3 FY2023Sep 30, 2023-$7.17M–
Q2 FY2023Jun 30, 2023-$7.72M–
Q1 FY2023Mar 31, 2023-$7.53M–
Q4 FY2022Dec 31, 2022-$7.80M–
Q3 FY2022Sep 30, 2022-$7.40M–
Q2 FY2022Jun 30, 2022-$7.18M–
Q1 FY2022Mar 31, 2022-$6.15M–
Q4 FY2021Dec 31, 2021-$5.85M–
Q3 FY2021Sep 30, 2021-$3.39M–
Q2 FY2021Jun 30, 2021-$3.05M–
Q1 FY2021Mar 31, 2021-$2.36M–
Q4 FY2020Dec 31, 2020-$2.31M–
Q3 FY2020Sep 30, 2020-$1.68M–
Q2 FY2020Jun 30, 2020-$2.87M–

More IN8bio figures

See a number that looks wrong?